OxyNov

OxyNov, founded in 2009 and based in Canada, is revolutionizing oxygen therapy with its flagship device, the FreeO2. The company's slogan "Revolutionizing oxygen therapy with the FreeO2: a device that optimizes every stage of treatment during hospital care" captures their commitment to innovation and excellence in respiratory care. OxyNov's mission is to enhance patient safety and quality of life while optimizing care in the face of increasing patient numbers and rising hospitalization costs. The FreeO2, an automated oxygen therapy system, is at the core of OxyNov's cutting-edge technologies. It adjusts oxygen flow to the patient's needs in real time, thereby preventing both hyperoxia and hypoxemia. Additionally, it enables the monitoring of the patient's cardiopulmonary condition, adding an extra layer of safety and precision to the therapy process. In May 2017, OxyNov secured a significant $500.00K investment in a venture round. The investors backing the company at that time were Desjardins-Innovatech and Campus des Technologies de la Santé/CTS Healthcare, indicating the confidence of established entities in OxyNov's potential to reshape the landscape of oxygen therapy. As OxyNov continues to pioneer advancements in respiratory care, it presents an exciting opportunity for venture capitalists looking to invest in the future of health care technology.